Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
9.60
+0.09 (0.95%)
Market open: Aug 12, 2026, 11:15 AM EDT
9.70
+0.19 (2.00%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
| Name | Position |
|---|---|
| Dr. Ian Hodgson B.Sc., Ph.D. | Chief Operating Officer |
| Dr. Leonardo Viana Nicacio M.D. | Chief Medical Officer |
| Dr. Yuval Cohen Ph.D. | CEO & Director |
| Mr. G. Scott Goeken J.D., M.S. | General Counsel & Corporate Secretary |
| Mr. Nishant C. Saxena | Chief Business Officer |
| Mr. Sean F. Moran CPA, M.B.A. | Chief Financial Officer |
| Ms. Christina Bertsch M.A. | Vice President of Human Resources |
| Date | Type | Document |
|---|---|---|
| 2026-08-06 | 10-Q | crbp-20260630.htm |
| 2026-07-06 | 8-K | crbp-20260702.htm |
| 2026-06-17 | S-8 | crbp-20260617.htm |
| 2026-05-29 | S-8 | crbp-20260529.htm |
| 2026-05-26 | 8-K | crbp-20260526.htm |
| 2026-05-21 | 8-K | crbp-20260519.htm |
| 2026-05-14 | 8-K | crbp-20260513.htm |
| 2026-05-12 | 8-K | crbp-20260512.htm |
| 2026-05-12 | 10-Q | crbp-20260331.htm |
| 2026-04-16 | DEFA14A | crbp_defa14a_2026_04_16.htm |